For Patients

Who is AVEO?

 

AVEO Pharmaceuticals is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to positively impact patients’ lives.

 

Additional Tivozanib Clinical Trials

In addition to TIVO-1, our ongoing Phase 3 clinical trial of oral, one capsule, once-daily tivozanib in patients with advanced RCC, we are currently conducting the following clinical trials of tivozanib in patients with different forms of cancer. We are also evaluating ficlatuzumab in combination with gefitinib in an ongoing Phase 2 clinical trial in patients with non-small cell lung cancer.

 

 

 

 

 

Access to AVEO Clinical Trials

 

To find out more about AVEO's ongoing clinical trials evaluating tivozanib and ficlatuzumab, please visit www.clinicaltrials.gov, or contact AVEO’s medical affairs department at medicalaffairs@aveopharma.com, or by phone at 617-299-5800 (option 1).

 

For additional patient resources online, please visit:

 

Kidney Cancer Association
American Cancer Association
Cancer Care
National Cancer Institute